Atrial Fibrillation – BMS 562247 – CV 185316

Location: Las Vegas

Stay: None

Gender: Male/Female

Ages: 18+

Smokers Allowed: Yes

Study Overview:

The purpose of this study is to determine if taking apixaban (Eliquis) for 6 months, is safer, in terms of side effect bleeding, than taking a Vitamin K Antagonist (such as warfarin) for 6 months, in patients who are also receiving medications (such as aspirin and/or Plavix) to prevent blood cells called platelets from forming clumps. Patients with an irregular heartbeat, such as Atrial Fibrillation (AF) or flutter, and who have had a recent procedure to open up blood vessels in the heart (angioplasty) may qualify to participate in the study. The results from this study will help physicians understand how to best combine medications that may help treat your heart conditions, while potentially reducing the side effect of bleeding that may occur when taking these types of medications together.

Enroll In This Study